Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer
Shikhar Sharma(Pfizer (United States)), Thomas A. Paul(Pfizer (United States)), Brendon J. Monahan(Monash University), Ian P. Street(Unknown), Aida Sacaan(Pfizer (United States)), Xinmeng Jasmine Mu(Pfizer (United States)), Patrick Bingham(Pfizer (United States)), Shinji Yamazaki, Pei‐Pei Kung(Pfizer (United States)), S.E. Greasley(University of British Columbia), Oleg Brodsky(Pfizer (United States)), Ylva E. Bozikis(Monash University), Colin A. Flaveny(Pfizer (United States)), Paul A. Stupple(Monash University), Karen A. Maegley(Pfizer (United States)), Hendrik Falk(Commonwealth Scientific and Industrial Research Organisation), Rhys Jones(Pfizer (United States)), Sean Uryu(Pfizer (United States)), Yong Zhang(Hebei Medical University), Jelena Petrovic(Cancer Research Institute), Scott C. Sutton(Pfizer (United States)), Chi-Yeh Chung(Salk Institute for Biological Studies), Hieu Lam(Pfizer (United States)), Joan Cao(Pfizer (United States)), Paul Richardson(Pfizer (United States)), Eric W. Johnson(The Fertilizer Institute), Eric C. Greenwald(Pfizer (United States))
Cited by 0
Related Papers
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
|Cell Reports|2016|936
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
|Cancer Discovery|2018|558